The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCRX | -10.94% | +90.84% | +13.8% | +7% |
| S&P | +14.5% | +93.32% | +14.09% | +1,342% |
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $163.35M | 49.4% |
| Gross Profit | $160.23M | 49.4% |
| Gross Margin | 98.09% | 0.0% |
| Market Cap | $1.87B | 47.0% |
| Market Cap / Employee | $3.23M | 0.0% |
| Employees | 580 | 8.2% |
| Net Income | $5.09M | 140.1% |
| EBITDA | $30.12M | 231.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $88.53M | 10.4% |
| Accounts Receivable | $91.18M | 32.6% |
| Inventory | 5 | 13.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $701.17M | -14.4% |
| Short Term Debt | $37.75M | 19.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -7.68% | 21.4% |
| Return On Invested Capital | -71.49% | 20.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $40.59M | 2208.4% |
| Operating Free Cash Flow | $40.77M | 2403.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -3.36 | -3.32 | -3.29 | -4.15 | 54.88% |
| Price to Sales | 3.81 | 3.46 | 3.21 | 3.53 | 5.89% |
| Price to Tangible Book Value | -3.36 | -3.32 | -3.29 | -4.15 | 54.88% |
| Price to Free Cash Flow TTM | 127.10 | - | |||
| Enterprise Value to EBITDA | 260.38 | -495.32 | 99.66 | 81.31 | -60.14% |
| Free Cash Flow Yield | 0.8% | - | |||
| Total Debt | $842.14M | $841.42M | $829.29M | $738.92M | -13.13% |
BCRX earnings call for the period ending December 31, 2024.
BCRX earnings call for the period ending September 30, 2024.
BCRX earnings call for the period ending June 30, 2024.
BCRX earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
